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Background: Long-term use of macrolide antibiotics is effective to prevent exacerbations in 
chronic obstructive pulmonary disease (COPD). As risks and side effects of long-term intervention 
outweigh the benefits in the general COPD population, the optimal dose, duration of treatment, and 
target population are yet to be defined. Hospitalization for an acute exacerbation (AE) of COPD 
may offer a targeted risk group and an obvious risk period for studying macrolide interventions.
Methods/design: Patients with COPD, hospitalized for an AE, who have a smoking history 
of $10 pack-years and had $1 exacerbation in the previous year will be enrolled in a multicenter, 
randomized, double-blind, placebo-controlled trial (NCT02135354). On top of a standardized 
treatment of systemic corticosteroids and antibiotics, subjects will be randomized to receive 
either azithromycin or placebo during 3 months, at an uploading dose of 500 mg once a day for 
3 days, followed by a maintenance dose of 250 mg once every 2 days. The primary endpoint is 
the time-to-treatment failure during the treatment phase (ie, from the moment of randomization 
until the end of intervention). Treatment failure is a novel composite endpoint defined as either 
death, the admission to intensive care or the requirement of additional systemic steroids or new 
antibiotics for respiratory reasons, or the diagnosis of a new AE after discharge.
Discussion: We investigate whether azithromycin initiated at the onset of a severe exacerbation, 
with a limited duration and at a low dose, might be effective and safe in the highest risk period 
during and immediately after the acute event. If proven effective and safe, this targeted approach 
may improve the treatment of severe AEs and redirect the preventive use of azithromycin in 
COPD to a temporary intervention in the subgroup with the highest unmet needs.
Keywords: COPD, acute exacerbation, macrolide antibiotics, azithromycin, physical 
activity, RCT
Introduction
Chronic obstructive pulmonary disease (COPD) is one of the major health challenges 
of the next decades and is currently estimated by Global Burden of Disease studies 
as the third leading cause of death worldwide.1 It is a chronic disease characterized 
by airflow limitation which is progressive, not fully reversible and associated with an 
abnormal inflammatory response of the lung to noxious particles and gases.2–4 The 
high burden of COPD resulting from its respiratory symptoms is further enhanced by 
recurrent exacerbations,5,6 which are triggered mainly by the acquisition of new strains 
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of respiratory pathogens or an increase in the concentration 
of bacteria colonizing the lower airways.7–9 Known to drive 
progressive lung function decline and physical inactivity, 
these acute events contribute significantly to morbidity and 
mortality, and the resulting hospitalizations impose a signifi-
cant strain on health care resource utilization.10,11
Although the spectrum of available COPD treatments 
reduces the frequency of exacerbations by approximately 
20%–30%,12–15 they are insufficient as many patients still 
experience at least one exacerbation a year of which one-
quarter requires hospitalization. A recent large European 
audit on COPD exacerbations in hospitalized patients 
revealed that these events were associated with 12% mor-
tality and 35% risk of readmission within 3 months after 
discharge.16 It is needless to argue that our current acute 
interventions are lacking effectiveness in a substantial 
proportion of the COPD admissions and that new inter-
ventions in this particular subset of patients are warranted. 
Bacterial infections are responsible for around half of the 
acute exacerbations (AEs) of COPD.17 Current guidelines 
therefore recommend antibiotic therapy for patients with 
more severe symptoms, with treatment typically lasting 
5–7 days. Although such intervention has shown to reduce 
the risk of subsequent exacerbations, relapse is common 
with some patients remaining at high risk for recurrent 
episodes for several weeks after the initial event. Failure 
may be related to inadequate antibiotic efficacy, but even 
with effective bacterial eradication, or in case of noninfec-
tious events, increased airway inflammation may persist for 
a prolonged period after discharge and will likely promote 
recurrence.9 Epidemiological data confirm that the risk for 
subsequent events peaks drastically during 90 days after 
discharge and clearly increases with every following hos-
pital admission.18 Disrupting the vicious cycle of one severe 
exacerbation introducing a subsequent one is therefore a 
promising interventional strategy.
Several randomized clinical trials have shown benefits of 
long-term macrolide treatment in a variety of chronic respiratory 
diseases, particularly in diffuse panbronchiolitis, cystic fibrosis, 
bronchiolitis obliterans syndrome post-lung transplantation, and 
bronchiectasis.19–23 The potential of long-term macrolide treatment 
for preventing COPD exacerbations has been recently confirmed 
in a large randomized controlled trial showing that chronic 
azithromycin therapy over 1 year, on top of standard inhalation 
therapy, reduced the risk of exacerbations by ∼30%.24 However, 
the long-term use of this class of antibiotics is not recommended 
in all patients with COPD as it is inevitably associated with bacte-
rial resistance and carries the risk for side effects such as hearing 
loss and life-threatening arrhythmias by the prolongation of the 
QT interval.25 Despite its potent effects and its proof of concept, 
uncertainty remains about the specific patient population that 
is most likely to benefit and also about the optimal dose and 
duration of the macrolide treatment.26 For these reasons, a recent 
update of the international treatment recommendations for COPD 
by the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) still did not incorporate azithromycin in its therapeutic 
arsenal.4 Reducing the dose and time course of the azithromycin 
intervention, as well as restricting the treatment to a subgroup of 
patients with COPD with the highest risk for future exacerbations, 
may overcome some of these concerns, and would therefore be 
a major step forward to a targeted clinical use.25,27 Additionally, 
short courses of macrolides were shown to facilitate the weaning 
process in ventilator-associated pneumonia and to shorten the 
time to resolution of pneumonia by approximately 40%.28 In AEs 
of asthma, 10 days of neomacrolides resulted in a significant 
symptom improvement compared to placebo.29 In line with these 
immediate therapeutic benefits for other acute respiratory diseases, 
azithromycin therapy, initiated at the onset of acute COPD exacer-
bations requiring hospital admission, may also improve short-term 
outcomes of hospitalization and prevent early relapse.
In this randomized, double-blind, placebo-controlled 
trial, the main aim is to assess whether a targeted course of 
low-dose azithromycin for 3 months, initiated at the onset of 
a severe AE requiring hospitalization, might be effective and 
safe in the highest risk period, that is, during and immediately 
after the acute event.
Content
This paper describes the BACE (the Belgian trial with 
azithromycin for acute COPD exacerbations requiring hos-
pitalization; clinicaltrial.gov number: NCT02135354) study 
design and its novel contributions to the current clinical 
research in the management of AEs of COPD. These include 
a study protocol designed to be embedded in a real-life hospi-
talization setting following an AE, assessing the efficacy and 
safety of a dose- and time-limited treatment with azithromy-
cin for prevention in the highest risk period, not only during 
but also immediately after the acute event. Furthermore, as a 
primary endpoint, we evaluate the time-to-treatment failure, 
a novel combined clinical endpoint defined as either death, 
the admission to intensive care or requirement of additional 
systemic steroids or new antibiotics for respiratory reasons, 
or the diagnosis of a new AE after discharge.
Methodology
Study design
The BACE trial is an investigator-initiated, multicenter, ran-
domized, double-blind, placebo-controlled trial. Besides the 
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lead center at the University Hospital in Leuven, patients will 
also be recruited from six academic and 13 nonacademic hos-
pitals within Belgium. A maximum total of 500 patients will be 
enrolled by the established consortium within a 2-year inclusion 
period. The first patient was included in August 2014. The end 
of the trial is defined by the last visit of all included patients.
Study population
All patients with COPD, 18 years or older, hospitalized for 
an AE and treated with standard therapy, will be asked to 
participate in the BACE trial.
In order to observe changes in the treatment (or treat-
ment failure) during and after hospitalization, the GOLD-
recommended therapy during an AE requiring hospitalization 
(which includes systemic steroids, antibiotics, and short-
acting bronchodilators)30 was fixed to a standard regimen 
(Table 1). This regimen is in line with recent literature on 
the dose of systemic steroids31–33 and the Infectious Diseases 
Advisory Board Belgian guidelines for antibiotic use in AEs 
of COPD requiring hospitalization.
Inclusion and exclusion criteria
All patients must have an established diagnosis of COPD made 
by a medical doctor (based on clinical history and a pulmo-
nary function test), with a history of $1 exacerbation in the 
preceding year for which a course of systemic steroids and/or 
antibiotics was started, must be current or past smokers with a 
smoking history of $10 pack-years, and must have a normal 
QTc value confirmed by an electrocardiogram taken at admis-
sion. Automated QTc values, calculated according to Bazett’s 
formula, and predefined cutoff criteria, that is, #450 ms for 
male and #470 ms for female, were used to determine the eli-
gibility. The same formula was used throughout the patient’s 
trial participation to evaluate QT prolongation.
The main exclusion criteria are contraindications to 
azithromycin, respiratory insufficiency at the moment of ran-
domization, chronic systemic steroid use (.4 mg methylpred-
nisolone/day for $2 months), and the active use of macrolide 
antibiotics during $2 weeks preceding inclusion.
The full list of exclusion criteria is given in Table 2.
Intervention
Eligible patients consenting to participation will be random-
ized (1:1) to receive either azithromycin (Azitromycine CF; 
Centrafarm Nederland B.V., Etten-Leur, the Netherlands) or 
placebo tablets of identical appearance (Apotheek Haagse 
Ziekenhuizen, Den Haag, the Netherlands) on top of maximal 
standardized therapy. Within 48 hours after hospital admis-
sion, a 3-month treatment phase with azithromycin or placebo 
is initiated at an uploading dose of 500 mg once a day for 
3 days and subsequently administered at a lower maintenance 
dose of 250 mg every 2 days for the remainder of the 90-day 
Table 1 Fixed regimen of standard therapy for an acute COPD 
exacerbation requiring hospitalization
Therapy Specifications
Systemic steroids Methylprednisolone 40 mg IV or 32 mg PO OD 
for 5 days (switch IV to PO as soon as possible)
Antibiotics
First choice Amoxi–Clavulanate 1 g IV QID or 2 g PO BID 
for 7 days (or alternative regimen of 1 g IV QID 
or 875/125 mg PO tID for 7 days)
Alternatives Moxifloxacin 400 mg IV or 400 mg PO OD for 
5 days
In case of: Intolerance or allergy to Amoxi–Clavulanate
Clinical failure on GP-initiated Amoxi–Clavulanate 
treatment
Anti-pseudomonas antibiotics
In case of: Bronchiectasis
History of positive cultures for pseudomonas
High risk of pseudomonas
Clinical failure on GP-initiated treatment
Short-acting 
bronchodilators
Via inhalation
respiratory support Oxygen
Noninvasive ventilationa
Mechanical ventilationa
Note: aConsidered exclusion criteria if needed at the moment of randomization.
Abbreviations: COPD, chronic obstructive pulmonary disease; IV, intravenous; 
PO, per os; OD, once a day; QID, four times a day; BID, two times a day; tID, three 
times a day; GP, general practitioner.
Table 2 Full list of exclusion criteria
Exclusion criteria
1 Mechanical or noninvasive ventilation at the moment 
of randomization
2 long Qt interval on ECG: Qtc .450 ms for male or .470 ms 
for female
3 History of life-threatening arrhythmias
4 Myocardial infarction (NStEMI or StEMI) less than 6 weeks 
before starting the study drug
5 unstable angina pectoris or acute myocardial infarction  
(NStEMI or StEMI) at admission
6 Concomitant use of a drug with high risk for long Qt interval and 
torsade de pointes (amiodarone, flecainide, procainamide, sotalol, 
droperidol, haldol, citalopram, other macrolides)
7 Documented uncorrected severe hypokalemia (K+ ,3.0 mmol/l) 
or hypomagnesemia (Mg2+ ,0.5 mmol/l)
8 Chronic systemic steroids (.4 mg methylprednisolone/day 
for $2 months)
9 Actual use of macrolides for at least 2 weeks
10 Allergy to macrolides
11 Active cancer treatment
12 life expectancy ,3 months
13 Pregnant or breast-feeding subjects. Woman of childbearing 
potential must have a pregnancy test performed and a negative 
result must be documented before starting the treatment
Abbreviations: ECG, electrocardiogram; NStEMI, non-St elevation myocardial 
infarction; StEMI, St elevation myocardial infarction.
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treatment period. Patients will then be followed up for an 
additional 6 months to evaluate the recurrence rate after the 
withdrawal of study drug.
The BACE trial study design is presented in Figure 1.
rationale for duration and dose of 
azithromycin
In 2011, Albert et al showed that azithromycin reduces 
the risk of future COPD exacerbations by ∼30% on top 
of standard inhalation therapy when given chronically for 
over a year at a dose of 250 mg once daily. Careful observa-
tion of the data revealed that a major part of the reduction 
in exacerbations is already obtained within 90 days after 
treatment onset. Thereafter, the curves representing the 
proportion of patients free from AEs may still diverge, 
whereas after 6 months of treatment, a more steady and 
equal decline for both the placebo and intervention arm 
are reached.24 Remarkably, in the study by Wong et al on 
the reduction of exacerbations in bronchiectasis, in which 
azithromycin was stopped after 6 months of treatment, 
benefits persisted for another 6 months of follow-up.23 
It indicates that the withdrawal of azithromycin after 
prolonged intake of 3–6 months is reasonable to consider 
and sufficient for interrupting the circle of inflammation, 
infection, and relapse.
In addition to the optimal duration for the azithromycin 
intervention, uncertainty remains about the ideal dose to 
target therapeutic serum and tissue levels.26 Earlier pharma-
cokinetic studies have found that a dose of 500 mg corre-
sponded to serum peak levels of 0.4 µg/mL with a half-life 
of 40–68 hours. With repeated administration, lung tissue 
levels increased 75-fold and persisted even after serum levels 
declined.34,35 Therefore, several experts believe that 250 mg 
of azithromycin three times weekly is probably sufficient to 
obtain all therapeutic benefits while reducing potential side 
effects, although there are no specific data to support this 
in COPD.25,36
Objectives and endpoints
The primary objective is to prove the effectiveness of azithro-
mycin on top of maximal standardized therapy in the acute 
treatment of COPD exacerbations that require hospitalization. 
A secondary objective is to prove the safety, without losing 
effectiveness, by reducing the dose and duration of a current 
and everlasting treatment.
The primary clinical efficacy endpoint is the time-to-
treatment failure and will be evaluated within the period 
from randomization (day 1, from 1 hour after the first 
intake of study drug) until the end of intervention (day 90, 
24 hours after the last intake of study drug). By using 
this endpoint, the potential short-term benefits of acute 
macrolide treatment, as well as the long-term benefits of 
prolonged treatment, are utilized. The combined endpoint 
is defined as either death, the admission to intensive care 
Figure 1 the BACE trial study design.
Abbreviations: BACE, the Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization; COPD, chronic obstructive pulmonary disease; D1, day 1; 
D1–3, days 1–3; D4–90, days 4–90; D270, day 270; OD, once a day.
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or the requirement of additional systemic steroids or new 
antibiotics for respiratory reasons, or the diagnosis of a new 
AE of COPD after discharge. Each of the components in 
the combined endpoint bears the same weight; once one 
is fulfilled, the primary endpoint is met. The use of this 
combined endpoint of treatment failure in the first 3 months 
is in line with earlier studies on the efficacy of systemic 
steroids during the AE37 and will avoid arbitrary clini-
cal decisions on whether recurrent symptoms or therapy 
needed is related to an incomplete resolution or to a new 
acute event.
Key secondary endpoints are the number of clinical 
failures at day 90, symptom COPD Assessment Test (CAT) 
score at day 90, and total days of steroid use at day 90. Other 
main secondary endpoints are the key secondary endpoints 
at day 270 and endpoints assessed at the end of intervention 
(day 90) and the end of follow-up (day 270) including time 
to new exacerbation, number of new exacerbations, total days 
of hospitalization, total days of intensive care, quality-of-life 
(European Quality-of-Life – 5 Dimensions [EQ5D] question-
naire) and symptom assessments (CAT, modified Medical 
Research Council, and the Speech, Spatial, and Qualities of 
Hearing Scale – 5 Items questionnaires), forced expiratory 
volume in 1 second, total dose of systemic steroids, total 
days of antibiotic use, number of home physician contacts, 
and average costs of hospitalization.
randomization and masking
Patients will be randomly assigned in a 1:1 ratio to receive 
either azithromycin or placebo, with a permuted block size 
of ten and sequential assignment, stratified by the center. 
Randomization and distribution of the study drug are per-
formed by the hospital pharmacy of the University Hospital of 
Ghent based on an online generated randomization schedule 
(http://www.randomization.com). Unique randomization 
codes are locally obtained through a secured Web-based 
program. Participants, investigators, and research assistants 
are blinded to treatment allocation.
Clinical procedures
The study protocol is designed to be embedded in a real-life 
hospitalization setting following an AE. All screening tests 
to assess eligibility are part of the routine assessment in the 
emergency department. After initiating the intervention, 
study visits are scheduled to coincide with clinical routine 
practice in Belgium.
The study consists of the following visits that occur during 
hospitalization: randomization (day 1 is the first day of study 
drug administration), start of maintenance dose (day 4, +3-day 
window allowed for all actions with the exception of switch-
ing from the uploading to the maintenance dose), and day of 
discharge (day X, left at investigators discretion). After dis-
charge, subjects will be followed at the outpatient department 
at 1 month after discharge (day X +28, +14-day window), the 
end of intervention (day 90, allowed from day 86 up to day 
105), and the end of follow-up (day 270, +14-day window). 
Telephone calls are scheduled bimonthly (day 150 and day 
210, ±7-day window) between the end of intervention and 
the end of follow-up. Patients are instructed to complete a 
diary with biweekly questionnaires for symptom evaluation, 
medication changes and the detection of new exacerbations, 
general practitioner visits, or new hospitalizations. Adherence 
is assessed by study drug accountability and diary completion. 
Data collected at each visit are shown in Table 3. Performed 
in addition to clinical routine are the following tests: for the 
assessment of the impact of COPD – CAT questionnaire; 
level of dyspnea – modified Medical Research Council 
questionnaire; quality of life – EQ5D questionnaire; antibi-
otic resistance – bacterial and fungal culture on spontaneous 
sputum samples; cardiac toxicity – electrocardiogram; and 
the screening of hearing decrement – the Speech, Spatial and 
Qualities of hearing scale – 5-item questionnaire.
Substudies
PrOactive substudy
During and after AEs, patients with COPD are profoundly 
inactive and failure to increase physical activity (PA) is 
associated with relapse. Moreover, physical inactivity is 
known to be associated with cardiovascular and metabolic 
morbidity and is one of the strongest predictors of mortality 
in COPD.6 Recurrent AEs have a deleterious impact on PA 
and treatments implemented to reduce the burden of an AE 
may spin off in faster recovery of PA.
In a subgroup of the BACE trial, PA levels will be 
addressed with easy-to-wear portable devices (DynaPort®; 
McRoberts B.V., the Hague, the Netherlands), recently thor-
oughly validated by the PROactive consortium for the use 
in COPD.38 We hypothesize that with an effective  medical 
intervention, differences in the recovery of PA will be appre-
ciated when measuring 30 subjects in each treatment arm, 
offering considerable benefits in the long run.
Randomized patients willing to participate in the substudy 
will not only follow the standard protocol but also wear the 
activity monitor for 7 days after discharge (day X), at the end 
of intervention (day 90) and at the end of follow-up (day 270). 
This device is not only registering PA for 7 days but is also 
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coupled to a standardized and patient-validated questionnaire 
on physical activities, which needs to be filled out at day 8 
to cover a recall period of 7 (monitored) days.
Pharmacoeconomic substudy
A second subanalysis of the BACE trial will include a detailed 
cost-effectiveness study. This multicenter randomized trial 
executed in one country will provide an excellent tool for pre-
cise health economic assessments. In a first approach, rough 
estimates on savings of direct costs in the entire study cohort 
will be made by an evaluation of average costs in Flanders 
for a single hospitalization day at a respiratory ward, a day at 
intensive care, an emergency visit, a home physician contact, 
and for an antibiotic and/or steroid course. A more detailed 
cost-effectiveness and cost-utility analysis at 3-month and 
9-month intervals will only be performed in case significant 
clinical benefits are found in favor of the active treatment.
For this purpose, medical resource use data will be col-
lected not only retrospectively via hospital invoices (direct 
costs including medications, physician visits, laboratory 
tests, technical examinations, medical imaging, and hospital 
stay) but also prospectively via patient diaries, to cover 
direct and indirect costs (relating to time, convenience, and 
transportation) during the entire outpatient period and will 
be linked to the EQ5D scores.
Ethical approval
The BACE trial is being carried out according to the Good Clin-
ical Practice Guidelines and the principles of the Declaration 
of Helsinki. Documented approval has been obtained from the 
Leading Ethics Committee (Commissie Medische Ethiek UZ 
KU Leuven, Leuven, Belgium - affiliated to UZ KU Leuven) 
and the competent authority (Federaal Agentschap voor 
Geneesmiddelen en Gezondheidsproducten [Federal Agency 
for Medicines and Health Products], Brussels, Belgium). 
All patients must provide a written informed consent accord-
ing to the International Conference on Harmonization Good 
Clinical Practice Guidelines and local legal requirements. 
Randomized patients, willing to participate in the PROactive 
and/or pharmacoeconomic substudy, will have to give an 
informed consent for the additional measures related to either 
of the substudies. However, individual patients can choose 
to opt out for these measures and only to participate in the 
medical intervention study, the BACE trial.
Statistics
Efficacy population
The primary endpoint will be evaluated in the intention-
to-treat population, that is, all randomized patients. 
As a secondary analysis, the primary endpoint will also be 
evaluated in the per-protocol population (not including drop-
outs and including only patients with satisfactory adherence 
to the intake of the study drug).
Sample size calculation
Two hundred and fifty subjects per group, 500 subjects in 
total, will yield 80% power to show a significant difference 
in the primary endpoint at a two-sided significance level of 
0.05. Sample size calculation is based on a survival analysis 
using a logrank test assuming proportional hazards, a clinical 
failure in at least 45% of the placebo arm within 3 months 
(based on 35% readmissions in the Belgian COPD popula-
tion in the European COPD audit,16 a proportion of 50% 
with a new exacerbation within 4 months after randomiza-
tion in the randomized trial with vitamin D enrolling similar 
but stable patients,39 and a 20% treatment failure within 
8 weeks in the MAESTRAL study looking at mild exacer-
bations40), a 35% relative improvement with azithromycin 
intervention (hazard ratio (HR) =0.65; HR of 0.73 for time 
to first exacerbation,24 HR of 0.5 for time to the resolu-
tion of ventilator-associated pneumonia28), and taking into 
account a maximal amount of 25% of dropouts. After the 
inclusion of 125 patients, recruitment was somewhat lower 
than anticipated and the observed dropout was also lower 
(16/125 [12.8%]). Therefore, it was opted to foresee an 
interim analysis for efficacy and futility when 300 patients 
reach their 90-day follow-up. Assuming a lower dropout 
rate of 17% and the same other assumptions as mentioned 
earlier, the trial remains powered at 80% with a sample size 
of 500 patients and a total number of 177 events. Sample size 
calculation was done using EAST Version 6.3.
Interim analysis
As cardiac safety and the risk of QT prolongation are major 
concerns during an AE requiring hospital admission, an 
interim safety and efficacy analysis will be performed as soon 
as 300 patients have completed their 3-month visit. They will 
be tested for both efficacy and futility using the alpha- and 
beta-spending functions of O’Brien–Fleming.41 The amount of 
information will be assessed by the number of observed events 
over the required number of 177 events to obtain 80% power. 
Full details will be available in a statistical analysis plan. 
These analyses will be performed by an independent safety 
committee consisting of a cardiologist and a statistician.
Statistical analysis
All patients randomized will be analyzed according to the 
intention-to-treat principle. The primary efficacy endpoint 
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will be analyzed by means of a logrank test. In addition, a 
hazard ratio with a 95% confidence interval from a Cox pro-
portional hazards model will be provided. A serial gatekeep-
ing method42 will be used to control the family-wise type I 
error of the key secondary endpoints that will be addressed 
in the following hierarchy: number of clinical failures at 
day 90, symptom CAT score at day 90, and total days of 
steroid use at day 90. All other secondary outcomes and all 
analyses performed at day 90 and day 270 will be considered 
as exploratory. A 5% significance level will be used. Full 
details will be available in a statistical analysis plan which 
will be finalized before the interim analysis.
Data acquisition and analysis
Data will be collected in an electronic case report form by the 
local investigators and their dedicated clinical trial assistants, 
and will be monitored by the central study coordinators of 
the BACE trial blinded to the randomization code prior to 
a total database lock. There is no external clinical research 
organization. Particular attention will go to the adjudication 
of the primary endpoint as this is a composite one of which 
all components bear the same weight. For the interim as well 
as the final analysis, the database will also be checked for 
outliers after, respectively, the 300th patient has completed 
his day 90 visit and after the last patient has completed his 
day 270 follow-up visit. These outliers will be linked to the 
original on-site documents for revision via queries to the local 
investigators and clinical trial assistants. After database lock, 
the randomization code will be broken and the statistical 
analysis will be performed according to a comprehensive 
statistical plan which defines primary, secondary, safety, and 
subgroup analyses.
Conclusion
This randomized placebo-controlled trial aims to establish an 
appropriate but more restricted use of azithromycin during and 
immediately after hospital admission for a severe exacerba-
tion of COPD to overcome the highest risk period for treat-
ment failure, relapse, and death. The proposed intervention 
will deal not only with short-term in-hospital outcomes but 
also with the relapse rate during the 3 months after discharge, 
a period known to have the highest risk for deterioration.
By reducing the dose and the duration of treatment with 
azithromycin and by targeting the treatment to acute periods 
with the highest risk for treatment failure, benefits may coun-
terbalance potential side effects of macrolides, which may 
result in a new treatment strategy for severe AE of COPD. 
If proven to be safe and effective, a breakthrough in the acute 
treatment setting will be obtained and the chronic use of 
high-dose azithromycin in a large and poorly defined 
 population of patients with COPD, with inherent risks and 
side effects, will be reserved for well-defined subgroups.
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